Presented at ESMO Congress 2024 – Barcelona, Spain
This abstract highlights how true single-circulating tumor cell (CTC) genomics can identify enriched therapy-resistance signatures in advanced colorectal cancer patients. The findings underscore the potential of single-cell approaches to guide personalized treatment strategies by capturing molecular detail often missed in bulk or ctDNA-based profiling.